Lipella Pharmaceuticals Inc. (LIPO) intrinsic value & 10-year financials
Lipella Pharmaceuticals Inc. (LIPO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 5 fiscal years revenue grew 27.4% a year to $536.4K, with an average return on invested capital of 2235.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.00
- Market cap
- $629
- Revenue (FY2024)
- $536.4K
- Revenue growth (5-yr CAGR)
- 27.4%
- ROIC (10-yr avg)
- 2235.8%
- Free cash flow (FY2024)
- —
LIPO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2024 | $536.4K | -$5.0M | -$4.79 | — | -947.2% | 4921.8% |
| FY2023 | $449.6K | -$4.6M | -$0.77 | -$3.2M | -1055.6% | 2044.7% |
| FY2022 | $184.2K | -$2.6M | -$0.64 | — | -1406.3% | 3024.1% |
| FY2021 | $259.3K | -$1.9M | -$0.55 | — | -738.7% | -1047.5% |
| FY2020 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
LIPELLA PHARMACEUTICALS INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
LIPELLA PHARMACEUTICALS INC. has earned high returns on invested capital, averaging 22.4% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
LIPELLA PHARMACEUTICALS INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, LIPELLA PHARMACEUTICALS INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-159.10 per share.